The later findings proved that, PODXL associates with advanced tumor phenotype in some cancers, including breast cancer [1, 13], colorectal cancer [5, 14–16], esophageal cancer [17], gastric cancer [17–19], glioblastoma multiforme [20], lung adenocarcinoma [21], oral squamous cell carcinoma [4, 22], ovarian cancer [23], pancreatic cancer [24–27], prostate cancer [28, 29], renal cell carcinoma [30], urothelial bladder cancer [31], and so on. Here, PODXL is linked to lung adenocarcinoma.